A Novel Off-the-Shelf TCR Bispecific Platform for Cancer Immunotherapy
Time: 2:00 pm
day: DAY ONE TRACK 2 B
Details:
- Plug and play approach for making TCR engagers integrated with our clinical validated TCE technology
- Our approach was optimized from different design for best activity and IgG-like manufacturing properties
- The platform was validated by testing several TCR targets in vitro and in vivo with potent preclinical activity
